Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Fosun Kite Approved to Launch CAR-T as Second Line Therapy for B-Cell Lymphoma

publication date: Jul 19, 2023

Shanghai Fosun Kite Biotechnology was approved to launch Yikaida®, its CAR-T product, as a second-line therapy in China for adult large B-cell lymphoma (r/r LBCL). Patients must have failed first-line immunochemotherapy or relapsed within 12 months. Previously, Yikaida, the first CAR-T product available in China as a second-line rr/LBCL therapy, was approved as a third-line treatment. In 2017, Fosun formed a JV with LA’s Kite Pharma to develop Kite's CAR-T immuno-oncology drug for China in a $95 million agreement that included $20 million for China development costs. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital